

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/025,052	12/19/2001	Mark C. Estes	G&C 130.36-US-01	5934	
22462	7590 12/15/2004		EXAMINER		
GATES & COOPER LLP			MENDEZ, MANUEL A		
HOWARD HUGHES CENTER 6701 CENTER DRIVE WEST, SUITE 1050			ART UNIT	PAPER NUMBER	
LOS ANGELES, CA 90045			3763		
			DATE MAILED: 12/15/2004	DATE MAILED: 12/15/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)	,			
Office Action Summary		10/025,052		ESTES ET AL.				
		Examiner		Art Unit				
		Manuel Mendez		3763				
 Period for	The MAILING DATE of this communication app Reply	ears on the cover	sheet with the co	orrespondence ad	idress			
THE M - Extensi after SI - If the pi - If NO pi - Failure Any rep	RTENED STATUTORY PERIOD FOR REPLY AILING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.13 IX (6) MONTHS from the mailing date of this communication. eriod for reply specified above is less than thirty (30) days, a reply eriod for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, ply received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, howe within the statutory min will apply and will expire s cause the application to	over, may a reply be time imum of thirty (30) days SIX (6) MONTHS from to become ABANDONED	ely filed will be considered time he mailing date of this co) (35 U.S.C. § 133).				
Status								
1)⊠ F	Responsive to communication(s) filed on 15 Se	eptember 2004.		•				
2a)⊠ T	This action is FINAL . 2b) ☐ This action is non-final.							
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositio	n of Claims							
4. 5)□ C 6)⊠ C 7)□ C	Claim(s) 23-58 is/are pending in the application a) Of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) 23-58 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	wn from considera						
Applicatio	n Papers							
9)□ T	he specification is objected to by the Examine	r.						
10)∐ T	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
	Applicant may not request that any objection to the o		-					
	Replacement drawing sheet(s) including the correction he oath or declaration is objected to by the Ex	•	• • • • •		• •			
Priority un	nder 35 U.S.C. § 119							
a)	cknowledgment is made of a claim for foreign All b) Some * c) None of: Certified copies of the priority documents Copies of the certified copies of the priority documents Copies of the certified copies of the priority documents All Copies of the certified copies of the priority documents Copies of the certified copies of the priorical depolication from the International Bureau Certified copies of the priority documents Copies of the certified copies of the priorical depolication from the International Bureau Certified copies of the priority documents Copies of the priority documents	s have been rece s have been rece nty documents ha u (PCT Rule 17.2	vived. vived in Application ve been receiver (a)).	on No d in this National	Stage			
Attachment(s	5)							
1) Notice	of References Cited (PTO-892)		Interview Summary (
3) 🔲 Informa	of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	5) 🔲	Paper No(s)/Mail Da Notice of Informal Pa Other:		O-152)			

Art Unit: 3763

DETAILED ACTION

After conducting a secondary search, the examiner of record has located relevant prior pertinent to the prosecution of this application. Accordingly, the following rejections are presented for applicant's review.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -


- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Application/Control Number: 10/025,052

Art Unit: 3763

Claims 23 and 41 are rejected under 35 U.S.C. 102(b) as being anticipated by Orkin, et al.



The cited patent shows in figure 3, an infusion pump (84) and a control system (102) for controlling medication delivery profiles and a plurality of suspend functions capable of separately suspending a plurality of medication delivery profiles. As figure 11b demonstrates, the apparatus shown in figure 3, is capable of separately suspending the medication profiles of fluids 1, 2, and/or 3.

The examiner notes for the record, that all the structural elements disclosed by the applicant in the cited claims are anticipated by the teachings of Orkin, et al. More importantly, the programming of the control system of Orkin, et al., demonstrates the conventionality of infusing simultaneously multiple medications with different infusion profiles in relation to time, and also, different suspending profiles in relation to time.

Art Unit: 3763

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 24-40 and 42-58 are rejected under 35 U.S.C. 103(a) as being unpatentable over Orkin, et al., and/or Kern, et al., in view of Lebel, et al., U.S. Patent No. 6,562,001, Lebel, et al., U.S. Patent No. 6,810,290, and in further view of Rodler.

As discussed above the Orkin, et al., Patent discloses an infusion pump (84) and a control system (102) for controlling medication delivery profiles and a plurality of suspend functions capable of separately suspending a plurality of medication delivery profiles. The Kern, et al., Patent also discloses an infusion pump(s) and a control system for controlling medication delivery profiles and a plurality of suspend functions capable of separately suspending a plurality of medication delivery profiles.

Both, the Orkin, et al., and Kern, et al., Patents do not expressly disclose the programming of the respective control systems with <u>basal</u>, <u>square wave</u>, and <u>dual wave profiles</u>, and further more, the use of program safety measures in case of operator error when inputting infusion data. However, these enhancements are conventional in the art as evidenced by the teachings of **Lebel**, et al., U.S. Patent No. 6,810,290, and **Rodler**.

Both Lebel, et al., Patents demonstrate the conventionality of programming a pump processor to infuse particular profiles including square wave, dual wave and/or

Art Unit: 3763

basal. Additionally, in column 2, lines 3-13, the specification of the Rodler Patent suggests that enhancing an infusion system with safety features in case of operator error is well known in the art. Accordingly, the modification of the processors disclosed by the **Orkin, et al.**, and **Kern, et al.**, Patents with algorithms representing <u>basal</u>, square wave, and dual wave profiles, and the addition of safety prevention features would have been considered obvious in view of the teachings of the cited patents.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manuel Mendez whose telephone number is 703-308-2221. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Manuel Mendez

Primary Examiner Art Unit 3763

MM